<?xml version='1.0' encoding='utf-8'?>
<document id="26392328"><sentence text="In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors."><entity charOffset="65-75" id="DDI-PubMed.26392328.s1.e0" text="dabigatran" /></sentence><sentence text="To quantify the drug-drug interactions between dabigatran etexilate (DE) and proton pump inhibitors (PPI) and in particular the role of P-gp activity modulation"><entity charOffset="47-67" id="DDI-PubMed.26392328.s2.e0" text="dabigatran etexilate" /><entity charOffset="69-71" id="DDI-PubMed.26392328.s2.e1" text="DE" /><pair ddi="false" e1="DDI-PubMed.26392328.s2.e0" e2="DDI-PubMed.26392328.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26392328.s2.e0" e2="DDI-PubMed.26392328.s2.e1" /></sentence><sentence text=" In the first part of the study, efflux ratios of DE were evaluated using the caco-2 cell line in the presence of pantoprazole, omeprazole, rabeprazole, lansoprazole and ciclosporin A (positive control)"><entity charOffset="114-126" id="DDI-PubMed.26392328.s3.e0" text="pantoprazole" /><entity charOffset="128-138" id="DDI-PubMed.26392328.s3.e1" text="omeprazole" /><entity charOffset="140-151" id="DDI-PubMed.26392328.s3.e2" text="rabeprazole" /><entity charOffset="153-165" id="DDI-PubMed.26392328.s3.e3" text="lansoprazole" /><entity charOffset="170-183" id="DDI-PubMed.26392328.s3.e4" text="ciclosporin A" /><entity charOffset="50-62" id="DDI-PubMed.26392328.s3.e5" text="DE" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e5" e2="DDI-PubMed.26392328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e0" e2="DDI-PubMed.26392328.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e0" e2="DDI-PubMed.26392328.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e0" e2="DDI-PubMed.26392328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e0" e2="DDI-PubMed.26392328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e0" e2="DDI-PubMed.26392328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e1" e2="DDI-PubMed.26392328.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e1" e2="DDI-PubMed.26392328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e1" e2="DDI-PubMed.26392328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e1" e2="DDI-PubMed.26392328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e2" e2="DDI-PubMed.26392328.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e2" e2="DDI-PubMed.26392328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e2" e2="DDI-PubMed.26392328.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e3" e2="DDI-PubMed.26392328.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26392328.s3.e3" e2="DDI-PubMed.26392328.s3.e4" /></sentence><sentence text=" The two PPI that reduced the efflux ratio of dabigatran to the greatest and least extent, respectively, were used during the second part of the study, comprising a single-centre, randomised, open-label study with an incomplete Latin square design"><entity charOffset="46-56" id="DDI-PubMed.26392328.s4.e0" text="dabigatran" /></sentence><sentence text=" Nine healthy volunteers received DE (150 mg) alone, DE (150 mg) with the first PPI and DE (150 mg) with the second PPI in randomised sequence"><entity charOffset="34-43" id="DDI-PubMed.26392328.s5.e0" text="DE" /><entity charOffset="53-62" id="DDI-PubMed.26392328.s5.e1" text="DE" /><entity charOffset="88-97" id="DDI-PubMed.26392328.s5.e2" text="DE" /><pair ddi="false" e1="DDI-PubMed.26392328.s5.e0" e2="DDI-PubMed.26392328.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26392328.s5.e0" e2="DDI-PubMed.26392328.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s5.e0" e2="DDI-PubMed.26392328.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s5.e1" e2="DDI-PubMed.26392328.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s5.e1" e2="DDI-PubMed.26392328.s5.e2" /></sentence><sentence text=" Dabigatran plasma concentration and thrombin time were measured in blood samples withdrawn at 11 time points after each treatment"><entity charOffset="1-11" id="DDI-PubMed.26392328.s6.e0" text="Dabigatran" /></sentence><sentence text=" Models were built using a nonlinear mixed-effect modelling approach" /><sentence text=" Omeprazole and rabeprazole were the two PPI that reduced the efflux ratio of DE least and most, respectively"><entity charOffset="1-11" id="DDI-PubMed.26392328.s8.e0" text="Omeprazole" /><entity charOffset="16-27" id="DDI-PubMed.26392328.s8.e1" text="rabeprazole" /><entity charOffset="78-88" id="DDI-PubMed.26392328.s8.e2" text="DE" /><pair ddi="false" e1="DDI-PubMed.26392328.s8.e0" e2="DDI-PubMed.26392328.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26392328.s8.e0" e2="DDI-PubMed.26392328.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s8.e0" e2="DDI-PubMed.26392328.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26392328.s8.e1" e2="DDI-PubMed.26392328.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26392328.s8.e1" e2="DDI-PubMed.26392328.s8.e2" /></sentence><sentence text=" The PK model was based on an inverse Gaussian absorption process with one compartment" /><sentence text=" The relationship between dabigatran concentration and thrombin time was considered linear"><entity charOffset="26-36" id="DDI-PubMed.26392328.s10.e0" text="dabigatran" /></sentence><sentence text=" Some PK profiles had dramatically low concentration values due to poor absorption" /><sentence text=" These profiles were clustered using a between subject model mixture with interoccasion variability" /><sentence text=" The concomitant administration of PPI did not significantly change dabigatran pharmacokinetics"><entity charOffset="68-78" id="DDI-PubMed.26392328.s13.e0" text="dabigatran" /></sentence><sentence text=" DE is subject to high absorption variability, precluding evaluation of the effect of PPI on its pharmacokinetics"><entity charOffset="1-10" id="DDI-PubMed.26392328.s14.e0" text="DE" /></sentence><sentence text=" " /></document>